context stringlengths 838 4.39k | question stringclasses 3
values | answers dict | metadata stringlengths 95 109 |
|---|---|---|---|
To compare the efficacy and side effects and the effect on aqueous humor dynamics of 0.005% latanoprost applied topically once daily with 0.5% timolol given twice daily for 12 months to patients with pigmentary glaucoma.
Prospective, randomized, double-masked, clinical study.
Thirty-six patients affected with bilater... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:10080213", "type": "list", "id": "glaucoma:10080213:major_claim"} |
To compare the efficacy and side effects and the effect on aqueous humor dynamics of 0.005% latanoprost applied topically once daily with 0.5% timolol given twice daily for 12 months to patients with pigmentary glaucoma.
Prospective, randomized, double-masked, clinical study.
Thirty-six patients affected with bilater... | Every claim in the abstract, as written. | {
"text": [
"further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,",
"in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% tim... | {"field": "claim", "group": "glaucoma:10080213", "type": "list", "id": "glaucoma:10080213:claim"} |
To compare the efficacy and side effects and the effect on aqueous humor dynamics of 0.005% latanoprost applied topically once daily with 0.5% timolol given twice daily for 12 months to patients with pigmentary glaucoma.
Prospective, randomized, double-masked, clinical study.
Thirty-six patients affected with bilater... | Every premise in the abstract, as written. | {
"text": [
"Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.",
"Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol a... | {"field": "premise", "group": "glaucoma:10080213", "type": "list", "id": "glaucoma:10080213:premise"} |
To report the longer term results of a randomized, clinical trial comparing the 350-mm2 and the 500-mm2 Baerveldt glaucoma implants.
Extended follow-up on a randomized, controlled trial.
Between March 1991 and April 1993, 107 patients with uncontrolled intraocular pressure (IOP) due to non-neovascular glaucoma associ... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:10599663", "type": "list", "id": "glaucoma:10599663:major_claim"} |
To report the longer term results of a randomized, clinical trial comparing the 350-mm2 and the 500-mm2 Baerveldt glaucoma implants.
Extended follow-up on a randomized, controlled trial.
Between March 1991 and April 1993, 107 patients with uncontrolled intraocular pressure (IOP) due to non-neovascular glaucoma associ... | Every claim in the abstract, as written. | {
"text": [
"The longer term results show that the 350-mm2 Baerveldt implant is more successful than the 500-mm2 implant for overall IOP control.",
"Interval comparisons indicate a higher rate of success for the 350-mm2 implant in the first, second, third, fourth, and fifth years of implantation."
],
"ans... | {"field": "claim", "group": "glaucoma:10599663", "type": "list", "id": "glaucoma:10599663:claim"} |
To report the longer term results of a randomized, clinical trial comparing the 350-mm2 and the 500-mm2 Baerveldt glaucoma implants.
Extended follow-up on a randomized, controlled trial.
Between March 1991 and April 1993, 107 patients with uncontrolled intraocular pressure (IOP) due to non-neovascular glaucoma associ... | Every premise in the abstract, as written. | {
"text": [
"The overall success rates were 87% for the 350-mm2 group and 70% for the 500-mm2 group (P = 0.05).",
"The life-table success rates declined over time for both implant groups, from a high of 98% for the 350-mm2 group and 92% for the 500-mm2 group at 1 year to a cumulative success rate of 79% for t... | {"field": "premise", "group": "glaucoma:10599663", "type": "list", "id": "glaucoma:10599663:premise"} |
Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects. Brinzolamide 1.0%, a new topical ocular carbonic anhydrase inhibitor, is effective apparently without significant systemic side effects. This study was performed to establish the long-term safety and efficacy of brinzola... | Every major claim in the abstract, as written. | {
"text": [
"Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects."
],
"answer_start": [
2
]
} | {"field": "major_claim", "group": "glaucoma:10682964", "type": "list", "id": "glaucoma:10682964:major_claim"} |
Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects. Brinzolamide 1.0%, a new topical ocular carbonic anhydrase inhibitor, is effective apparently without significant systemic side effects. This study was performed to establish the long-term safety and efficacy of brinzola... | Every claim in the abstract, as written. | {
"text": [
"Brinzolamide produced less ocular discomfort (burning/stinging) than timolol, and total carbonic anhydrase inhibition levels remained below that known to cause systemic side effects.",
"Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three ti... | {"field": "claim", "group": "glaucoma:10682964", "type": "list", "id": "glaucoma:10682964:claim"} |
Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects. Brinzolamide 1.0%, a new topical ocular carbonic anhydrase inhibitor, is effective apparently without significant systemic side effects. This study was performed to establish the long-term safety and efficacy of brinzola... | Every premise in the abstract, as written. | {
"text": [
"All regimens produced clinically relevant and statistically significant (P<.05) intraocular pressure reductions from baseline.",
"Mean changes in intraocular pressure trough measurements ranged from -2.7 to -3.9 mm Hg with brinzolamide twice-daily dosing and -2.8 to -3.8 mm Hg three times daily d... | {"field": "premise", "group": "glaucoma:10682964", "type": "list", "id": "glaucoma:10682964:premise"} |
To compare the effects on intraocular pressure (IOP) and side effects of monotherapy with either latanoprost or dorzolamide in patients with glaucoma or ocular hypertension.
224 patients with open angle glaucoma or ocular hypertension were recruited to a 3 month open labelled study. Previous glaucoma medications were... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:10837379", "type": "list", "id": "glaucoma:10837379:major_claim"} |
To compare the effects on intraocular pressure (IOP) and side effects of monotherapy with either latanoprost or dorzolamide in patients with glaucoma or ocular hypertension.
224 patients with open angle glaucoma or ocular hypertension were recruited to a 3 month open labelled study. Previous glaucoma medications were... | Every claim in the abstract, as written. | {
"text": [
"Both drugs were well tolerated systemically and locally.",
"Latanoprost was superior to dorzolamide in reducing the IOP, judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP."
],
"answer_start": [
1119,
1176
]
} | {"field": "claim", "group": "glaucoma:10837379", "type": "list", "id": "glaucoma:10837379:claim"} |
To compare the effects on intraocular pressure (IOP) and side effects of monotherapy with either latanoprost or dorzolamide in patients with glaucoma or ocular hypertension.
224 patients with open angle glaucoma or ocular hypertension were recruited to a 3 month open labelled study. Previous glaucoma medications were... | Every premise in the abstract, as written. | {
"text": [
"After 3 months, latanoprost reduced mean baseline diurnal IOP from 27.2 (SD 3.0) mm Hg by 8.5 (3.3) mm Hg.",
"The corresponding figures for dorzolamide were 27.2 (3.4) and 5.6 (2.6) mm Hg.",
"The difference of 2.9 mm Hg (95% CI: 2.3-3.6) was highly significant (p<0.001, ANCOVA).",
"Latano... | {"field": "premise", "group": "glaucoma:10837379", "type": "list", "id": "glaucoma:10837379:premise"} |
To compare the clinical success rates and quality of life impact of brimonidine 0.2% with timolol 0.5% in newly diagnosed patients naive to glaucoma therapy.
A prospective, multicenter, randomized, double-masked, clinical effectiveness trial in which the clinical outcomes of twice daily brimonidine tartrate 0.2% were... | Every major claim in the abstract, as written. | {
"text": [
"Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension."
],
"answer_start": [
1762
]
} | {"field": "major_claim", "group": "glaucoma:10877373", "type": "list", "id": "glaucoma:10877373:major_claim"} |
To compare the clinical success rates and quality of life impact of brimonidine 0.2% with timolol 0.5% in newly diagnosed patients naive to glaucoma therapy.
A prospective, multicenter, randomized, double-masked, clinical effectiveness trial in which the clinical outcomes of twice daily brimonidine tartrate 0.2% were... | Every claim in the abstract, as written. | {
"text": [
"As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart."
],
"answer_start": [
1575
]
} | {"field": "claim", "group": "glaucoma:10877373", "type": "list", "id": "glaucoma:10877373:claim"} |
To compare the clinical success rates and quality of life impact of brimonidine 0.2% with timolol 0.5% in newly diagnosed patients naive to glaucoma therapy.
A prospective, multicenter, randomized, double-masked, clinical effectiveness trial in which the clinical outcomes of twice daily brimonidine tartrate 0.2% were... | Every premise in the abstract, as written. | {
"text": [
"Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.",
"The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.",
"Few patients reported a specific adverse event",
"with the exception of a slightly highe... | {"field": "premise", "group": "glaucoma:10877373", "type": "list", "id": "glaucoma:10877373:premise"} |
To compare the additional intraocular pressure-lowering effect of latanoprost 0.005% administered once daily with that of pilocarpine 2% administered three times daily in patients with primary open-angle glaucoma or ocular hypertension currently on monotherapy with timolol 0.5% twice daily.
In a 6-month, multicenter,... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:10901475", "type": "list", "id": "glaucoma:10901475:major_claim"} |
To compare the additional intraocular pressure-lowering effect of latanoprost 0.005% administered once daily with that of pilocarpine 2% administered three times daily in patients with primary open-angle glaucoma or ocular hypertension currently on monotherapy with timolol 0.5% twice daily.
In a 6-month, multicenter,... | Every claim in the abstract, as written. | {
"text": [
"From the data we conclude that the additivity of latanoprost 0.005% is at least as effective as pilocarpine 2% t.i.d. in reducing IOP when added to eyes currently on monotherapy with timolol 0.5% b.i.d.",
"Latanoprost was better tolerated than pilocarpine 2% eye drops in this study.",
"The in... | {"field": "claim", "group": "glaucoma:10901475", "type": "list", "id": "glaucoma:10901475:claim"} |
To compare the additional intraocular pressure-lowering effect of latanoprost 0.005% administered once daily with that of pilocarpine 2% administered three times daily in patients with primary open-angle glaucoma or ocular hypertension currently on monotherapy with timolol 0.5% twice daily.
In a 6-month, multicenter,... | Every premise in the abstract, as written. | {
"text": [
"For both treatments the diurnal IOP reduction after 6 months was statistically significant (P<0.001).",
"IOP (mean+/-SD) was reduced from 23.3+/-2.8 to 17.8+/-2.8 (-5.6) mmHg in the latanoprost 0.005% group and from 23.0+/-3.2 to 18.5+/-2.4 (-4.8) mmHg in pilocarpine 2% t.i.d.-treated eyes.",
... | {"field": "premise", "group": "glaucoma:10901475", "type": "list", "id": "glaucoma:10901475:premise"} |
To compare the short- and intermediate-term results of two commonly used glaucoma surgical procedures, trabeculectomy and Ahmed glaucoma valve implant.
A randomized clinical trial was performed at two international centers. One eye each of consecutive patients requiring glaucoma surgery for intraocular pressure contr... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:11020403", "type": "list", "id": "glaucoma:11020403:major_claim"} |
To compare the short- and intermediate-term results of two commonly used glaucoma surgical procedures, trabeculectomy and Ahmed glaucoma valve implant.
A randomized clinical trial was performed at two international centers. One eye each of consecutive patients requiring glaucoma surgery for intraocular pressure contr... | Every claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "claim", "group": "glaucoma:11020403", "type": "list", "id": "glaucoma:11020403:claim"} |
To compare the short- and intermediate-term results of two commonly used glaucoma surgical procedures, trabeculectomy and Ahmed glaucoma valve implant.
A randomized clinical trial was performed at two international centers. One eye each of consecutive patients requiring glaucoma surgery for intraocular pressure contr... | Every premise in the abstract, as written. | {
"text": [
"With a mean follow-up of 9.7 months, the trabeculectomy group had statistically lower intraocular pressures at weeks 6 to 15 (12.6 mm Hg vs 16.4 mm Hg) and months 11 to 13 (11.4 mm Hg vs 17.2 mm Hg) than the Ahmed implant group.",
"Compared with preoperative status, no statistically significant d... | {"field": "premise", "group": "glaucoma:11020403", "type": "list", "id": "glaucoma:11020403:premise"} |
To report a randomized clinical trial of postoperative subconjunctival injections of low-dose 5-fluorouracil in patients undergoing primary trabeculectomy.
In a prospective, randomized clinical trial, 40 eyes of 40 patients were randomized to the low-dose 5-fluorouracil group and received three subconjunctival inject... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:11124286", "type": "list", "id": "glaucoma:11124286:major_claim"} |
To report a randomized clinical trial of postoperative subconjunctival injections of low-dose 5-fluorouracil in patients undergoing primary trabeculectomy.
In a prospective, randomized clinical trial, 40 eyes of 40 patients were randomized to the low-dose 5-fluorouracil group and received three subconjunctival inject... | Every claim in the abstract, as written. | {
"text": [
"Enhancement of success in this group of patients may require a larger total dose of 5-fluorouracil."
],
"answer_start": [
1267
]
} | {"field": "claim", "group": "glaucoma:11124286", "type": "list", "id": "glaucoma:11124286:claim"} |
To report a randomized clinical trial of postoperative subconjunctival injections of low-dose 5-fluorouracil in patients undergoing primary trabeculectomy.
In a prospective, randomized clinical trial, 40 eyes of 40 patients were randomized to the low-dose 5-fluorouracil group and received three subconjunctival inject... | Every premise in the abstract, as written. | {
"text": [
"Mean (+/-SD) preoperative and 1-year postoperative intraocular pressures in the 5-fluorouracil group were 26.9 (+/-9.5) and 15.3 (+/-5.8) mm Hg, respectively.",
"In the control group these were 25.9 (+/-8.1) mm Hg, and 15.8 (+/-5.1) mm Hg, respectively.",
"The patients who received 5-fluorour... | {"field": "premise", "group": "glaucoma:11124286", "type": "list", "id": "glaucoma:11124286:premise"} |
Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma. Yet it has not been clearly demonstrated that IOP-lowering treatment can reduce the incidence of glaucoma damage in patients with ocular hypertension. The aim of the current paper was to report th... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:11148810", "type": "list", "id": "glaucoma:11148810:major_claim"} |
Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma. Yet it has not been clearly demonstrated that IOP-lowering treatment can reduce the incidence of glaucoma damage in patients with ocular hypertension. The aim of the current paper was to report th... | Every claim in the abstract, as written. | {
"text": [
"Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.",
"In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and som... | {"field": "claim", "group": "glaucoma:11148810", "type": "list", "id": "glaucoma:11148810:claim"} |
Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma. Yet it has not been clearly demonstrated that IOP-lowering treatment can reduce the incidence of glaucoma damage in patients with ocular hypertension. The aim of the current paper was to report th... | Every premise in the abstract, as written. | {
"text": [
"After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);",
"the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.",
"Survival analysis sho... | {"field": "premise", "group": "glaucoma:11148810", "type": "list", "id": "glaucoma:11148810:premise"} |
To compare viscocanalostomy, a nonpenetrating procedure for glaucoma treatment, with trabeculectomy.
Randomized controlled trial.
Twenty white subjects (20 eyes) with open-angle glaucoma with no history of surgery were enrolled.
Ten subjects were randomly assigned to viscocanalostomy according to Stegmann's technique... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:11158795", "type": "list", "id": "glaucoma:11158795:major_claim"} |
To compare viscocanalostomy, a nonpenetrating procedure for glaucoma treatment, with trabeculectomy.
Randomized controlled trial.
Twenty white subjects (20 eyes) with open-angle glaucoma with no history of surgery were enrolled.
Ten subjects were randomly assigned to viscocanalostomy according to Stegmann's technique... | Every claim in the abstract, as written. | {
"text": [
"According to the results of this short-term study, trabeculectomy was more effective than viscocanalostomy in lowering IOP in glaucomatous eyes of white patients."
],
"answer_start": [
958
]
} | {"field": "claim", "group": "glaucoma:11158795", "type": "list", "id": "glaucoma:11158795:claim"} |
To compare viscocanalostomy, a nonpenetrating procedure for glaucoma treatment, with trabeculectomy.
Randomized controlled trial.
Twenty white subjects (20 eyes) with open-angle glaucoma with no history of surgery were enrolled.
Ten subjects were randomly assigned to viscocanalostomy according to Stegmann's technique... | Every premise in the abstract, as written. | {
"text": [
"After a mean follow-up of 6 months (range, 6-8 months), success was obtained in 5 of 10 cases in the trabeculectomy group and in 0 of 10 case in the viscocanalostomy group.",
"With Kaplan-Meier's method, subjects with viscocanalostomy showed shorter postoperative IOP-reduction periods than subjec... | {"field": "premise", "group": "glaucoma:11158795", "type": "list", "id": "glaucoma:11158795:premise"} |
To compare the intraocular pressure (IOP) reducing effect and safety of latanoprost 0.005% once daily with unoprostone 0.12% twice daily in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH).
An 8-week, double-masked, randomized, parallel-group, single-center clinical trial.
A total of 108 p... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:11158796", "type": "list", "id": "glaucoma:11158796:major_claim"} |
To compare the intraocular pressure (IOP) reducing effect and safety of latanoprost 0.005% once daily with unoprostone 0.12% twice daily in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH).
An 8-week, double-masked, randomized, parallel-group, single-center clinical trial.
A total of 108 p... | Every claim in the abstract, as written. | {
"text": [
"Latanoprost administered once daily was significantly more effective in reducing IOP compared with unoprostone administered twice daily in patients with POAG and OH."
],
"answer_start": [
1270
]
} | {"field": "claim", "group": "glaucoma:11158796", "type": "list", "id": "glaucoma:11158796:claim"} |
To compare the intraocular pressure (IOP) reducing effect and safety of latanoprost 0.005% once daily with unoprostone 0.12% twice daily in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH).
An 8-week, double-masked, randomized, parallel-group, single-center clinical trial.
A total of 108 p... | Every premise in the abstract, as written. | {
"text": [
"From an overall baseline of 24.1 mmHg, latanoprost reduced IOP by 6.7 mmHg (28%) and unoprostone reduced IOP by 3.3 mmHg (14%).",
"The difference between the groups of 3.4 mmHg was significant (P: < 0.001, analysis of covariance; 95% confidence interval [CI]: -4.7 to -2.1) in favor of latanoprost... | {"field": "premise", "group": "glaucoma:11158796", "type": "list", "id": "glaucoma:11158796:premise"} |
To compare the effect on intraocular pressure of latanoprost versus timolol plus dorzolamide in open-angle glaucoma.
Thirty-five patients with open-angle glaucoma were randomized, 18 to latanoprost once daily and 17 to timolol plus dorzolamide twice daily. Intraocular pressure and ocular side effects were recorded at... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:11167277", "type": "list", "id": "glaucoma:11167277:major_claim"} |
To compare the effect on intraocular pressure of latanoprost versus timolol plus dorzolamide in open-angle glaucoma.
Thirty-five patients with open-angle glaucoma were randomized, 18 to latanoprost once daily and 17 to timolol plus dorzolamide twice daily. Intraocular pressure and ocular side effects were recorded at... | Every claim in the abstract, as written. | {
"text": [
"Latanoprost administered once daily reduced the intraocular pressure at least as well as timolol plus dorzolamide twice daily in patients with open-angle glaucoma."
],
"answer_start": [
847
]
} | {"field": "claim", "group": "glaucoma:11167277", "type": "list", "id": "glaucoma:11167277:claim"} |
To compare the effect on intraocular pressure of latanoprost versus timolol plus dorzolamide in open-angle glaucoma.
Thirty-five patients with open-angle glaucoma were randomized, 18 to latanoprost once daily and 17 to timolol plus dorzolamide twice daily. Intraocular pressure and ocular side effects were recorded at... | Every premise in the abstract, as written. | {
"text": [
"Latanoprost reduced the intraocular pressure 1.09 and 1.58 mm Hg more than timolol plus dorzolamide after 2 weeks and 3 months of treatment, respectively.",
"These differences were statistically significant (p<0.05) at the end of the study.",
"After 3 months of treatment, 32.3% of the eyes in... | {"field": "premise", "group": "glaucoma:11167277", "type": "list", "id": "glaucoma:11167277:premise"} |
To compare the intraocular pressure)-lowering effect and side effects of latanoprost 0.005% once daily with unoprostone 0.12% twice daily.
Sixty patients with primary open-angle glaucoma or ocular hypertension were randomized to receive either latanoprost once daily in the evening and placebo once daily in the mornin... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:11336940", "type": "list", "id": "glaucoma:11336940:major_claim"} |
To compare the intraocular pressure)-lowering effect and side effects of latanoprost 0.005% once daily with unoprostone 0.12% twice daily.
Sixty patients with primary open-angle glaucoma or ocular hypertension were randomized to receive either latanoprost once daily in the evening and placebo once daily in the mornin... | Every claim in the abstract, as written. | {
"text": [
"Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open-angle glaucoma and ocular hypertension.",
"Both drugs were well tolerated with few ocular adverse events."
],
... | {"field": "claim", "group": "glaucoma:11336940", "type": "list", "id": "glaucoma:11336940:claim"} |
To compare the intraocular pressure)-lowering effect and side effects of latanoprost 0.005% once daily with unoprostone 0.12% twice daily.
Sixty patients with primary open-angle glaucoma or ocular hypertension were randomized to receive either latanoprost once daily in the evening and placebo once daily in the mornin... | Every premise in the abstract, as written. | {
"text": [
"After 1 month of treatment, latanoprost significantly reduced intraocular pressure (mean +/- SEM) by 6.1 +/- 0.5 mm Hg (P <.001) and unoprostone by 4.2 +/- 0.4 mm Hg (P <.001) adjusted from an overall baseline of 22.3 +/- 0.5 mm Hg and 23.2 +/- 0.4 mm Hg, respectively.",
"The difference of 1.9 mm... | {"field": "premise", "group": "glaucoma:11336940", "type": "list", "id": "glaucoma:11336940:premise"} |
To compare the intraocular pressure-lowering effect of latanoprost with that of dorzolamide when added to timolol.
This randomized, open-label study with two parallel groups was conducted in five centers in Greece. The study enrolled 148 patients with inadequately controlled open-angle or pseudoexfoliation glaucoma (... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:11558817", "type": "list", "id": "glaucoma:11558817:major_claim"} |
To compare the intraocular pressure-lowering effect of latanoprost with that of dorzolamide when added to timolol.
This randomized, open-label study with two parallel groups was conducted in five centers in Greece. The study enrolled 148 patients with inadequately controlled open-angle or pseudoexfoliation glaucoma (... | Every claim in the abstract, as written. | {
"text": [
"Drugs administered in both treatment groups were well tolerated.",
"This study clearly showed that the additive diurnal intraocular pressure-lowering effect of latanoprost is superior to that of dorzolamide in patients treated with timolol."
],
"answer_start": [
1409,
1474
]
} | {"field": "claim", "group": "glaucoma:11558817", "type": "list", "id": "glaucoma:11558817:claim"} |
To compare the intraocular pressure-lowering effect of latanoprost with that of dorzolamide when added to timolol.
This randomized, open-label study with two parallel groups was conducted in five centers in Greece. The study enrolled 148 patients with inadequately controlled open-angle or pseudoexfoliation glaucoma (... | Every premise in the abstract, as written. | {
"text": [
"The diurnal intraocular pressure reduction was significant in both groups (P < 0.001).",
"The mean intraocular pressure reduction from baseline was 32% for the latanoprost plus timolol group and 20% for the dorzolamide plus timolol group.",
"The least square estimate of the mean diurnal intra... | {"field": "premise", "group": "glaucoma:11558817", "type": "list", "id": "glaucoma:11558817:premise"} |
To evaluate the intraocular pressure-lowering efficacy and safety of travoprost 0.0015% and 0.004%, dosed daily in the evening compared with vehicle, in patients with open-angle glaucoma or ocular hypertension, whose intraocular pressure was not adequately controlled on timolol 0.5% twice daily (twice daily).
Subject... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:11730649", "type": "list", "id": "glaucoma:11730649:major_claim"} |
To evaluate the intraocular pressure-lowering efficacy and safety of travoprost 0.0015% and 0.004%, dosed daily in the evening compared with vehicle, in patients with open-angle glaucoma or ocular hypertension, whose intraocular pressure was not adequately controlled on timolol 0.5% twice daily (twice daily).
Subject... | Every claim in the abstract, as written. | {
"text": [
"Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension."
],
"answer_start": [
2055
]
} | {"field": "claim", "group": "glaucoma:11730649", "type": "list", "id": "glaucoma:11730649:claim"} |
To evaluate the intraocular pressure-lowering efficacy and safety of travoprost 0.0015% and 0.004%, dosed daily in the evening compared with vehicle, in patients with open-angle glaucoma or ocular hypertension, whose intraocular pressure was not adequately controlled on timolol 0.5% twice daily (twice daily).
Subject... | Every premise in the abstract, as written. | {
"text": [
"Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.",
"The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% co... | {"field": "premise", "group": "glaucoma:11730649", "type": "list", "id": "glaucoma:11730649:premise"} |
Many physicians recommend either brimonidine or latanoprost as firstline therapy for chronic open-angle glaucoma or ocular hypertension. However, a search of MEDLINE indicates that there have been few head-to-head comparisons of the 2 monotherapies in a clinical setting.
This study compared the clinical efficacy and ... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:11813932", "type": "list", "id": "glaucoma:11813932:major_claim"} |
Many physicians recommend either brimonidine or latanoprost as firstline therapy for chronic open-angle glaucoma or ocular hypertension. However, a search of MEDLINE indicates that there have been few head-to-head comparisons of the 2 monotherapies in a clinical setting.
This study compared the clinical efficacy and ... | Every claim in the abstract, as written. | {
"text": [
"This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.",
"Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy."
],
"answer_start": [
... | {"field": "claim", "group": "glaucoma:11813932", "type": "list", "id": "glaucoma:11813932:claim"} |
Many physicians recommend either brimonidine or latanoprost as firstline therapy for chronic open-angle glaucoma or ocular hypertension. However, a search of MEDLINE indicates that there have been few head-to-head comparisons of the 2 monotherapies in a clinical setting.
This study compared the clinical efficacy and ... | Every premise in the abstract, as written. | {
"text": [
"After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.",
"The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs ... | {"field": "premise", "group": "glaucoma:11813932", "type": "list", "id": "glaucoma:11813932:premise"} |
To compare the effect of treatment with latanoprost or brimonidine on intraocular pressure in patients with glaucoma or ocular hypertension and intraocular pressure inadequately controlled by monotherapy or dual therapy.
Three hundred seventy-nine patients with primary open-angle glaucoma or ocular hypertension were ... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:11912355", "type": "list", "id": "glaucoma:11912355:major_claim"} |
To compare the effect of treatment with latanoprost or brimonidine on intraocular pressure in patients with glaucoma or ocular hypertension and intraocular pressure inadequately controlled by monotherapy or dual therapy.
Three hundred seventy-nine patients with primary open-angle glaucoma or ocular hypertension were ... | Every claim in the abstract, as written. | {
"text": [
"Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after 6 months of treatment.",
"However, latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal intraocular pressure.",
"Latano... | {"field": "claim", "group": "glaucoma:11912355", "type": "list", "id": "glaucoma:11912355:claim"} |
To compare the effect of treatment with latanoprost or brimonidine on intraocular pressure in patients with glaucoma or ocular hypertension and intraocular pressure inadequately controlled by monotherapy or dual therapy.
Three hundred seventy-nine patients with primary open-angle glaucoma or ocular hypertension were ... | Every premise in the abstract, as written. | {
"text": [
"From an overall baseline mean intraocular pressure of 25.0 mm Hg, latanoprost monotherapy reduced mean diurnal intraocular pressure by 7.1 +/- 3.3 mm Hg (mean +/- SD, P < 0.001), whereas brimonidine monotherapy yielded an intraocular-pressure reduction of 5.2 +/- 3.5 mm Hg (P < 0.001).",
"This 1.... | {"field": "premise", "group": "glaucoma:11912355", "type": "list", "id": "glaucoma:11912355:premise"} |
To assess the intraocular pressure-lowering efficacy and the postoperative complication profile of viscocanalostomy versus trabeculectomy.
Sixty eyes of 60 patients with medically uncontrolled open-angle glaucoma were randomized either to the viscocanalostomy or to the trabeculectomy group of the trial. Viscocanalost... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:12169965", "type": "list", "id": "glaucoma:12169965:major_claim"} |
To assess the intraocular pressure-lowering efficacy and the postoperative complication profile of viscocanalostomy versus trabeculectomy.
Sixty eyes of 60 patients with medically uncontrolled open-angle glaucoma were randomized either to the viscocanalostomy or to the trabeculectomy group of the trial. Viscocanalost... | Every claim in the abstract, as written. | {
"text": [
"In eyes with open-angle glaucoma, viscocanalostomy is less effective in reducing intraocular pressure than standard filtering surgery.",
"postoperative complications are more frequent after filtering surgery."
],
"answer_start": [
1279,
1423
]
} | {"field": "claim", "group": "glaucoma:12169965", "type": "list", "id": "glaucoma:12169965:claim"} |
To assess the intraocular pressure-lowering efficacy and the postoperative complication profile of viscocanalostomy versus trabeculectomy.
Sixty eyes of 60 patients with medically uncontrolled open-angle glaucoma were randomized either to the viscocanalostomy or to the trabeculectomy group of the trial. Viscocanalost... | Every premise in the abstract, as written. | {
"text": [
"One day after surgery, mean (SD) intraocular pressure was 15.9 (5.2) for the trabeculectomy group (P <0.001) and 15.7 (3.6) for the viscocanalostomy group (P <0.001), respectively.",
"The success rate, defined as an intraocular pressure lower than 22 mm Hg without medication, was 56.7% in the tra... | {"field": "premise", "group": "glaucoma:12169965", "type": "list", "id": "glaucoma:12169965:premise"} |
To compare the safety and efficacy of intraoperative 5-fluorouracil (5-FU) or Intraoperative mitomycin C (MMC) in eyes undergoing primary trabeculectomy.
Prospective double-masked randomized clinical trial.
One hundred fifteen eyes of 103 patients with uncontrolled intraocular pressure (IOP) despite maximally tolerat... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:12383808", "type": "list", "id": "glaucoma:12383808:major_claim"} |
To compare the safety and efficacy of intraoperative 5-fluorouracil (5-FU) or Intraoperative mitomycin C (MMC) in eyes undergoing primary trabeculectomy.
Prospective double-masked randomized clinical trial.
One hundred fifteen eyes of 103 patients with uncontrolled intraocular pressure (IOP) despite maximally tolerat... | Every claim in the abstract, as written. | {
"text": [
"Our study suggests that intraoperative topical 5-FU is at least as effective as intraoperative topical MMC in reducing IOP of eyes undergoing primary trabeculectomy."
],
"answer_start": [
1292
]
} | {"field": "claim", "group": "glaucoma:12383808", "type": "list", "id": "glaucoma:12383808:claim"} |
To compare the safety and efficacy of intraoperative 5-fluorouracil (5-FU) or Intraoperative mitomycin C (MMC) in eyes undergoing primary trabeculectomy.
Prospective double-masked randomized clinical trial.
One hundred fifteen eyes of 103 patients with uncontrolled intraocular pressure (IOP) despite maximally tolerat... | Every premise in the abstract, as written. | {
"text": [
"A target IOP of 21 mm Hg at 6 months was achieved in 53 of 56 (95%) eyes in the 5-FU group and 54 of 57 (95%) eyes in the MMC group (P = 1.00).",
"At 12 months, 45 of 48 (94%) eyes in the 5-FU group met a target IOP of 21 mm Hg while 48 of 54 (89%) eyes in the MMC group did (P =.49).",
"The m... | {"field": "premise", "group": "glaucoma:12383808", "type": "list", "id": "glaucoma:12383808:premise"} |
To compare the intraocular pressure (IOP)-lowering effect and safety of latanoprost 0.005% once daily with that of unoprostone 0.15% twice daily for patients with primary open-angle glaucoma or ocular hypertension.
Randomized clinical trial.
In a prospective, 8-week, investigator-masked, parallel-group study conducte... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:12470755", "type": "list", "id": "glaucoma:12470755:major_claim"} |
To compare the intraocular pressure (IOP)-lowering effect and safety of latanoprost 0.005% once daily with that of unoprostone 0.15% twice daily for patients with primary open-angle glaucoma or ocular hypertension.
Randomized clinical trial.
In a prospective, 8-week, investigator-masked, parallel-group study conducte... | Every claim in the abstract, as written. | {
"text": [
"Over an 8-week period, latanoprost 0.005% once daily lowered IOP more than unoprostone 0.15% twice daily in patients with elevated IOP.",
"Both agents were safe and well tolerated."
],
"answer_start": [
1254,
1390
]
} | {"field": "claim", "group": "glaucoma:12470755", "type": "list", "id": "glaucoma:12470755:claim"} |
To compare the intraocular pressure (IOP)-lowering effect and safety of latanoprost 0.005% once daily with that of unoprostone 0.15% twice daily for patients with primary open-angle glaucoma or ocular hypertension.
Randomized clinical trial.
In a prospective, 8-week, investigator-masked, parallel-group study conducte... | Every premise in the abstract, as written. | {
"text": [
"The change in the mean +/- SD of the IOPs measured at 8:00 AM, 12 noon, and 4:00 PM was -7.2 +/- 3.2 mm Hg (28%) for latanoprost (25.3 +/- 2.8 mm Hg at baseline to 18.2 +/- 2.8 mm Hg at 8 weeks) and -3.9 +/- 2.6 mm Hg (15%) for unoprostone (25.5 +/- 3.3 mm Hg at baseline to 21.6 +/- 4.0 mm Hg; P <or=... | {"field": "premise", "group": "glaucoma:12470755", "type": "list", "id": "glaucoma:12470755:premise"} |
To determine whether treatment with betaxolol can delay or prevent the conversion from ocular hypertension to early glaucoma on the basis of visual field criteria, by means of a prospective, randomised, placebo-controlled trial.
Three hundred and fifty-six ocular hypertensives were randomized to treatment with either... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:12644943", "type": "list", "id": "glaucoma:12644943:major_claim"} |
To determine whether treatment with betaxolol can delay or prevent the conversion from ocular hypertension to early glaucoma on the basis of visual field criteria, by means of a prospective, randomised, placebo-controlled trial.
Three hundred and fifty-six ocular hypertensives were randomized to treatment with either... | Every claim in the abstract, as written. | {
"text": [
"the intent-to-treat analysis did not demonstrate a statistically significant reduction in the conversion rate in the betaxolol-treated group."
],
"answer_start": [
1762
]
} | {"field": "claim", "group": "glaucoma:12644943", "type": "list", "id": "glaucoma:12644943:claim"} |
To determine whether treatment with betaxolol can delay or prevent the conversion from ocular hypertension to early glaucoma on the basis of visual field criteria, by means of a prospective, randomised, placebo-controlled trial.
Three hundred and fifty-six ocular hypertensives were randomized to treatment with either... | Every premise in the abstract, as written. | {
"text": [
"Sixteen (13.2%) of 121 patients in the placebo group converted to glaucoma, compared with 12 (9.0%) of 134 patients in the betaxolol group.",
"The intent-to-treat analysis demonstrated no evidence of any difference in conversion rates between the betaxolol and placebo groups after 3 years.",
... | {"field": "premise", "group": "glaucoma:12644943", "type": "list", "id": "glaucoma:12644943:premise"} |
Carteolol is a beta-adrenoceptor antagonist with intrinsic sympathomimetic activity. Used topically to reduce intraocular pressure, it is typically applied twice daily. In an effort to provide a once-daily dosing regimen, carteolol was formulated with 1% alginic acid. Sodium alginate is a natural polymer product with... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:12660585", "type": "list", "id": "glaucoma:12660585:major_claim"} |
Carteolol is a beta-adrenoceptor antagonist with intrinsic sympathomimetic activity. Used topically to reduce intraocular pressure, it is typically applied twice daily. In an effort to provide a once-daily dosing regimen, carteolol was formulated with 1% alginic acid. Sodium alginate is a natural polymer product with... | Every claim in the abstract, as written. | {
"text": [
"The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.",
"The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by gl... | {"field": "claim", "group": "glaucoma:12660585", "type": "list", "id": "glaucoma:12660585:claim"} |
Carteolol is a beta-adrenoceptor antagonist with intrinsic sympathomimetic activity. Used topically to reduce intraocular pressure, it is typically applied twice daily. In an effort to provide a once-daily dosing regimen, carteolol was formulated with 1% alginic acid. Sodium alginate is a natural polymer product with... | Every premise in the abstract, as written. | {
"text": [
"At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.",
"At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectiv... | {"field": "premise", "group": "glaucoma:12660585", "type": "list", "id": "glaucoma:12660585:premise"} |
To compare the effectiveness and safety of viscocanalostomy and trabeculectomy in adults with uncontrolled open-angle glaucoma.
Single-masked, parallel-group, prospective, randomized 24-month trial, with 90% power to detect a clinically important difference between groups.
Fifty consecutive patients (50 eyes) with pr... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:12750084", "type": "list", "id": "glaucoma:12750084:major_claim"} |
To compare the effectiveness and safety of viscocanalostomy and trabeculectomy in adults with uncontrolled open-angle glaucoma.
Single-masked, parallel-group, prospective, randomized 24-month trial, with 90% power to detect a clinically important difference between groups.
Fifty consecutive patients (50 eyes) with pr... | Every claim in the abstract, as written. | {
"text": [
"Viscocanalostomy is an effective IOP-lowering procedure in white adults affected by open-angle glaucoma.",
"Trabeculectomy with postoperative 5-FU can probably provides lower IOPs but, with more numerous complications, greater discomfort, and more intensive postoperative management."
],
"answ... | {"field": "claim", "group": "glaucoma:12750084", "type": "list", "id": "glaucoma:12750084:claim"} |
To compare the effectiveness and safety of viscocanalostomy and trabeculectomy in adults with uncontrolled open-angle glaucoma.
Single-masked, parallel-group, prospective, randomized 24-month trial, with 90% power to detect a clinically important difference between groups.
Fifty consecutive patients (50 eyes) with pr... | Every premise in the abstract, as written. | {
"text": [
"At the end of the 24-month follow-up, IOP of 21 mmHg or less and more than 6 mmHg was achieved in 76% in group 1 (n = 19) and in 80% in group 2 (n = 20; log-rank P = 0.60);",
"an IOP between 6 and 16 mmHg was obtained in 56% in group 1 (n = 14) and in 72% in group 2 (n = 18; log-rank P = 0.17; Ka... | {"field": "premise", "group": "glaucoma:12750084", "type": "list", "id": "glaucoma:12750084:premise"} |
Brimonidine is a highly selective alpha-2 adrenergic receptor agonist with intraocular pressure (IOP) reducing effect. We conducted this study in Taiwan to compare the safety and efficacy of brimonidine 0.2% with timolol 0.5% for the treatment of glaucoma.
A prospective, randomized, single-masked, 1-month clinical ef... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:12908569", "type": "list", "id": "glaucoma:12908569:major_claim"} |
Brimonidine is a highly selective alpha-2 adrenergic receptor agonist with intraocular pressure (IOP) reducing effect. We conducted this study in Taiwan to compare the safety and efficacy of brimonidine 0.2% with timolol 0.5% for the treatment of glaucoma.
A prospective, randomized, single-masked, 1-month clinical ef... | Every claim in the abstract, as written. | {
"text": [
"Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.",
"It has a safe systemic profile with minimum effect on the heart."
],
"answer_start": [
2362,
2524
]
} | {"field": "claim", "group": "glaucoma:12908569", "type": "list", "id": "glaucoma:12908569:claim"} |
Brimonidine is a highly selective alpha-2 adrenergic receptor agonist with intraocular pressure (IOP) reducing effect. We conducted this study in Taiwan to compare the safety and efficacy of brimonidine 0.2% with timolol 0.5% for the treatment of glaucoma.
A prospective, randomized, single-masked, 1-month clinical ef... | Every premise in the abstract, as written. | {
"text": [
"At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.",
"The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).",
"At peak, the mean decreases from the ba... | {"field": "premise", "group": "glaucoma:12908569", "type": "list", "id": "glaucoma:12908569:premise"} |
To compare the efficacy and safety of topical bimatoprost (LUMIGAN; Allergan, Inc., Irvine, CA) once daily with that of topical combined timolol and dorzolamide (Cosopt; Merck and Co, Inc., Whitehouse Station, NJ) twice daily.
Prospective, randomized, double-masked, multicenter clinical trial.
One hundred seventy-sev... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:14644719", "type": "list", "id": "glaucoma:14644719:major_claim"} |
To compare the efficacy and safety of topical bimatoprost (LUMIGAN; Allergan, Inc., Irvine, CA) once daily with that of topical combined timolol and dorzolamide (Cosopt; Merck and Co, Inc., Whitehouse Station, NJ) twice daily.
Prospective, randomized, double-masked, multicenter clinical trial.
One hundred seventy-sev... | Every claim in the abstract, as written. | {
"text": [
"In individuals with glaucoma or ocular hypertension, uncontrolled on a topical beta-blocker alone, bimatoprost lowered IOP more consistently than did combined timolol and dorzolamide."
],
"answer_start": [
1682
]
} | {"field": "claim", "group": "glaucoma:14644719", "type": "list", "id": "glaucoma:14644719:claim"} |
To compare the efficacy and safety of topical bimatoprost (LUMIGAN; Allergan, Inc., Irvine, CA) once daily with that of topical combined timolol and dorzolamide (Cosopt; Merck and Co, Inc., Whitehouse Station, NJ) twice daily.
Prospective, randomized, double-masked, multicenter clinical trial.
One hundred seventy-sev... | Every premise in the abstract, as written. | {
"text": [
"Bimatoprost provided significantly greater IOP lowering compared with combined timolol and dorzolamide.",
"At the 8 AM measurements, bimatoprost lowered mean IOP 6.8 mmHg to 7.6 mmHg from baseline, whereas combined timolol and dorzolamide lowered mean IOP 4.4 to 5.0 mmHg from baseline (P<0.001)."... | {"field": "premise", "group": "glaucoma:14644719", "type": "list", "id": "glaucoma:14644719:premise"} |
To compare the efficacy of intraocular pressure (IOP) control of the Baerveldt-350 implant with tube ligature and the Ahmed valve in patients with refractory glaucoma.
Four hundred seventy glaucoma drainage device procedures from July 1995 to July 2001 (6 years) were reviewed retrospectively. Thirty-two cases of Baer... | Every major claim in the abstract, as written. | {
"text": [],
"answer_start": []
} | {"field": "major_claim", "group": "glaucoma:14704542", "type": "list", "id": "glaucoma:14704542:major_claim"} |
To compare the efficacy of intraocular pressure (IOP) control of the Baerveldt-350 implant with tube ligature and the Ahmed valve in patients with refractory glaucoma.
Four hundred seventy glaucoma drainage device procedures from July 1995 to July 2001 (6 years) were reviewed retrospectively. Thirty-two cases of Baer... | Every claim in the abstract, as written. | {
"text": [
"In a case-controlled comparison, the Baerveldt-350 implant and the Ahmed valve had similar IOP control and surgical outcomes in patients with refractory glaucoma at 1-year follow-up."
],
"answer_start": [
1624
]
} | {"field": "claim", "group": "glaucoma:14704542", "type": "list", "id": "glaucoma:14704542:claim"} |
End of preview. Expand in Data Studio
AbstRCT argument-component spans
Major claim, claim and premise argument-component spans in MEDLINE randomized-controlled-trial (RCT) abstracts (Mayer, Cabrio and Villata, ECAI 2020), expert-annotated with the brat tool (two annotators, adjudicated). Every context is the full abstract, not an isolated sentence: whether a sentence is a claim or a premise is judged against the rest of the abstract, which a per-sentence view would strip away.
Data-only mirror of the original brat distribution (revision
f856f1ca7514caa4094194b5623e84c159d9bf1d, archive SHA256 32150598d2e9). Reproduce with
scripts/repackage_dataset/abstrct_spans.py;
provenance.json records the archive hash, revision, native abstract counts and settings.
License: CC BY-NC-SA 4.0 (evidence).
Schema: context (the abstract), question, answers (text, answer_start: every span, not alternatives) and
JSON-string metadata (field is one of major_claim, claim, premise; group is {config}:{PMID}).
Every field is always asked; an abstract with none of a kind answers with null. Used by the extraction config of
tasksource-jev-typed-decisions
(neoplasm config, as abstrct/neoplasm).
neoplasm has the native train/dev/test split used for training. glaucoma and mixed are test-only
cross-domain transfer sets (no training abstracts) and are evaluation-only.
Citation
Please cite the original dataset:
@inproceedings{mayer2020ecai,
author = {Tobias Mayer and Elena Cabrio and Serena Villata},
title = {Transformer-Based Argument Mining for Healthcare Applications},
booktitle = {{ECAI} 2020 - 24th European Conference on Artificial Intelligence},
series = {Frontiers in Artificial Intelligence and Applications},
volume = {325},
pages = {2108--2115},
publisher = {{IOS} Press},
year = {2020},
}
Citing tasksource
If you use tasksource, its standardized task annotations, or datasets derived from them in published research, please cite the tasksource paper (Sileo, LREC-COLING 2024).
@inproceedings{sileo-2024-tasksource,
title = "tasksource: A Large Collection of {NLP} tasks with a Structured Dataset Preprocessing Framework",
author = "Sileo, Damien",
booktitle = "Proceedings of the 2024 Joint International Conference on Computational Linguistics, Language Resources and Evaluation (LREC-COLING 2024)",
month = may,
year = "2024",
address = "Torino, Italia",
publisher = "ELRA and ICCL",
url = "https://aclanthology.org/2024.lrec-main.1361",
doi = "10.63317/2h4pkr685mkq",
pages = "15655--15684",
}
- Downloads last month
- 18